Oxford/AstraZeneca coronavirus vaccine showed an acceptable safety profile in a study released in Lancet
AstraZeneca's experimental COVID-19 vaccine produced an immune response in early-stage trials in healthy volunteers, data shows reut.rs/30sQ0Vk
The vaccine, called AZD1222, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet reut.rs/30sQ0Vk 
AstraZeneca's first human trial of a COVID-19 vaccine shows promise, one of the leading candidates against a pandemic that has claimed more than 600,000 lives reut.rs/30sQ0Vk
'We need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 (COVID-19) infection, and for how long any protection lasts,' study lead author Andrew Pollard of the University of Oxford said. Read more reut.rs/32IEmbo
AstraZeneca's CEO says the vaccine is on track for September but the infection rate will affect the timetable reut.rs/32IEmbo
